Lara Meisner - Dec 20, 2022 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
General Counsel and Secretary
Signature
/s/ Kristian Humer, Attorney-in-Fact for Lara Meisner
Stock symbol
VRDN
Transactions as of
Dec 20, 2022
Transactions value $
-$103,592
Form type
4
Date filed
12/22/2022, 03:42 PM
Previous filing
Dec 19, 2022
Next filing
Jan 25, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRDN Common Stock Options Exercise $13.8K +600 $23.03 600 Dec 20, 2022 Direct
transaction VRDN Common Stock Sale -$16.8K -600 -100% $28.07 0 Dec 20, 2022 Direct F1
transaction VRDN Common Stock Options Exercise $376K +16.3K $23.03 16.3K Dec 21, 2022 Direct
transaction VRDN Common Stock Sale -$477K -16.3K -100% $29.19 0 Dec 21, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -600 -0.97% $0.00 61K Dec 20, 2022 Common Stock 600 $23.03 Direct F3
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -16.3K -26.74% $0.00 44.7K Dec 21, 2022 Common Stock 16.3K $23.03 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.03 to $28.09. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.01 to $29.5665. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.